Ardent Health director buys 11,260 shares

Ardent Health, Inc. director Robert DeMichiei reported an open-market purchase of Common Stock.

Rhea-AI Filing Summary

Ardent Health, Inc. director Robert DeMichiei reported an open-market purchase of Common Stock. He bought 11,260 shares at a weighted average price of $8.73 per share, increasing his direct holdings to 35,564 shares. The trade was executed through multiple transactions on June 5, 2026 at prices between $8.60 and $8.78.

Insider Trade Summary

Net Buyer: 11,260 shares

Net Buy 1 txn

Insider DeMichiei Robert

Role Director

Bought 11,260 shs ($98K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	11,260	$8.73	$98K

Holdings After Transaction: Common Stock — 35,564 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price of $8.73 per share. These shares were purchased in multiple transactions on 06/05/26 at prices ranging from $8.60 to $8.78, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased: 11,260 shares Weighted average price: $8.73 per share Post-transaction holdings: 35,564 shares +1 more

4 metrics

Shares purchased 11,260 shares Open-market purchase on June 5, 2026

Weighted average price $8.73 per share Average price across multiple trades on June 5, 2026

Post-transaction holdings 35,564 shares Common Stock directly owned after the purchase

Trade price range $8.60–$8.78 per share Individual trade prices on June 5, 2026

Key Terms

open-market purchase, weighted average price, Common Stock

3 terms

open-market purchase financial

"transaction_action is described as an open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in Column 4 is a weighted average price of $8.73 per share"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock financial

"security_title is listed as Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ardent Health (ARDT) disclose in this Form 4?

Ardent Health disclosed that director Robert DeMichiei purchased 11,260 shares of Common Stock. The open-market trade was reported at a weighted average price of $8.73 per share, executed across multiple transactions on June 5, 2026 within a defined price range.

How many Ardent Health (ARDT) shares does the director hold after this purchase?

Following the reported transaction, director Robert DeMichiei directly holds 35,564 shares of Ardent Health Common Stock. This figure reflects his position after acquiring 11,260 shares in the open market at a weighted average price of $8.73 per share on June 5, 2026.

At what prices did the Ardent Health (ARDT) insider buy shares on June 5, 2026?

The director’s purchases were executed at prices ranging from $8.60 to $8.78 per Ardent Health share. The reported transaction price of $8.73 is a weighted average across multiple trades that occurred that day, according to the Form 4 footnote disclosure.

Was the Ardent Health (ARDT) insider transaction an open-market purchase?

Yes. The Form 4 describes the transaction as an open-market purchase of Common Stock. Director Robert DeMichiei bought 11,260 shares directly, at a weighted average price of $8.73 per share, with a disclosed trade range between $8.60 and $8.78 on June 5, 2026.

Who is the reporting person in the Ardent Health (ARDT) Form 4 filing?

The reporting person is director Robert DeMichiei. The filing shows he made an open-market purchase of 11,260 Ardent Health Common Stock shares and now directly owns 35,564 shares following the June 5, 2026 transactions reported to the Securities and Exchange Commission.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 12:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeMichiei Robert

(Last) (First) (Middle)

340 SEVEN SPRINGS WAY, SUITE 100

(Street)

BRENTWOOD TENNESSEE 37027

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ardent Health, Inc. [ ARDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		P		11,260	A	$8.73(1)	35,564	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price of $8.73 per share. These shares were purchased in multiple transactions on 06/05/26 at prices ranging from $8.60 to $8.78, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Stephen C. Petrovich, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)